Effectiveness of Vancomycin Loading Therapy
Information source: Samsung Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Infection
Intervention: Vancomycin HCL (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Samsung Medical Center Official(s) and/or principal investigator(s):
Kyong Ran Peck, MD, Principal Investigator, Affiliation: Samsung Medical Center
Overall contact:
Kyong Ran Peck, MD, Phone: +82-2-3410-0322, Email: krpeck@skku.edu
Summary
The goal of tish clinical research study is to identify that loading of vancomycin can
faciliate rapid attainment of target trough serum vancomycin concentration.
Clinical Details
Official title: Effectiveness of Vancomycin Loading Therapy
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Time duration for concentration of vancomycin to reach target trough of 15-20 mg/L
Secondary outcome: Adverse event rate in each arm, including nephrotoxicity and rash.
Detailed description:
The Study drug
- Vancomycin : a glycopeptide antibiotic, is the first line agent in the treatment of
methicillin resistant stapylococcus aureus
Study design : Randomized controlled trials
Study Drug Administration
- If your doctor believes you are eligible, and you agree to take part in thish study,
you will be randomized to two treatment groups.
Eligibility
Minimum age: 20 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Admission to Samsung Medical Center MICU and general wards for infectious diseases
and hematology division
- Patients with SIRS (systemic inflammatory response syndrome)
- Intravenous vancomycin therapy deemed necessary
Exclusion Criteria:
- Age less than 20 years
- Age more than 75 years
- Current renal insufficiency defined as estimated Glomerular filtration rate <
50mg/min/1. 73 m2 by MDRD equation
- History of adverse events to vancomycin 5. Pregant woman
Locations and Contacts
Kyong Ran Peck, MD, Phone: +82-2-3410-0322, Email: krpeck@skku.edu
Samsung Medical Center, Seoul 135-710, Korea, Republic of; Not yet recruiting
Kyong Ran Peck, MD, Phone: +82-2-3410-0322, Email: krpeck@skku.edu
So Yeon Park, MD, Phone: +82-3410-0329, Email: miunori26@hanmail.net
Kyong Ran Peck, MD, Principal Investigator
So Yeon Park, MD, Sub-Investigator
Additional Information
Starting date: June 2012
Last updated: June 19, 2012
|
